Read this issue’s cover story titled “Specialists navigate changing, challenging landscape of geographic atrophy management.” More knowledge about the diagnosis and manageme ...

Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and ...

Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring systemic exposure characteristics distinct from antibody-based agents.

Information Minister Ataullah Tarar on Wednesday said jailed former prime minister Imran Khan would be allowed to speak with ...

Women over 50 face increased eye health risks post-menopause due to hormonal shifts. Conditions like dry eye, cataracts, glaucoma, and age-related macular degeneration become more prevalent.

The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and brought new changes and challenges in clinical practice, workflow and ...

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA ...

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in 1H 2027 Intend to initiate Phase 3 ...

An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.

Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong ...

Harrow, Inc. is rapidly evolving into a dominant US ophthalmic pharma player, with a 30-fold revenue increase since 2015 and ...

Apellis (APLS) stock gains as Roth launches its coverage with a Buy rating and a $31 target, citing its lead asset Syfovre.